IRMD vs GEHC vs SYK vs BSX vs MDT

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). GE HealthCare Technologies Inc. (GEHC) offers the better valuation at 13. 5x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate IRadimed Corporation (IRMD) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GE HealthCare Technologies Inc.

(GEHC) is the cheapest at 13. 5x versus IRadimed Corporation at 49. 6x. On forward P/E, GE HealthCare Technologies Inc. is actually cheaper at 13. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IRadimed Corporation wins at 0. 58x versus Medtronic plc's 36. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, IRadimed Corporation (IRMD) delivered a total return of +214.

1%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: IRMD returned +431. 3% versus GEHC's +6. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

30β versus GE HealthCare Technologies Inc. 's 1. 32β — meaning GEHC is approximately 341% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 94% for GE HealthCare Technologies Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to 4. 8% for GE HealthCare Technologies Inc.. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IRadimed Corporation (IRMD) is the more profitable company, earning 26.

8% net margin versus 10. 1% for GE HealthCare Technologies Inc. — meaning it keeps 26. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRMD leads at 31. 2% versus 13. 4% for GEHC. At the gross margin level — before operating expenses — IRMD leads at 76. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IRadimed Corporation (IRMD) is the more undervalued stock at a PEG of 0. 58x versus Medtronic plc's 36. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, GE HealthCare Technologies Inc. (GEHC) trades at 13. 0x forward P/E versus 42. 9x for IRadimed Corporation — 30. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, MDT (3.

6% yield), IRMD (1. 3% yield), SYK (1. 1% yield), GEHC (0. 2% yield) pay a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 1% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, GEHC: +6. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IRMD is a small-cap quality compounder stock; GEHC is a mid-cap deep-value stock; SYK is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock. IRMD, SYK, MDT pay a dividend while GEHC, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.